Who owns Eikon Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of EIKN from SEC Form 13F filings across 98 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 98 institutions disclosed 31.7M shares of Eikon Therapeutics, Inc. worth $254.2M — about 58.5% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
98
13F holders
$254.2M
value, 2026 filers
58.5%
of shares outstanding (31.7M sh)
30
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of EIKN's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 5.5M | $44.4M | 0.0% | 10.2% | +10.5% |
| 2 | BlackRock, Inc. | 4.9M | $39.1M | 0.0% | 9% | +13.7% |
| 3 | Foresite Capital Management IV, LLC | 1.9M | $15.6M | 6.2% | 3.6% | 0.0% |
| 4 | Merck & Co., Inc. | 1.7M | $13.4M | 1.6% | 3.1% | 0.0% |
| 5 | T. Rowe Price Investment Management, Inc. | 1.6M | $13.2M | 0.0% | 3% | +2.6% |
| 6 | Foresite Capital Management V, LLC | 1.3M | $10.6M | 3.7% | 2.4% | 0.0% |
| 7 | Capital World Investors | 1.2M | $9.5M | 0.0% | 2.2% | 0.0% |
| 8 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.1M | $8.9M | 0.0% | 2.1% | +10.5% |
| 9 | ALLIANCEBERNSTEIN L.P. | 1.1M | $8.5M | 0.0% | 1.9% | +63.9% |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 1.0M | $8.2M | 0.0% | 1.9% | +10.1% |
| 11 | EcoR1 Capital, LLC | 855,634 | $6.9M | 0.3% | 1.6% | +16.8% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 754,499 | $6.1M | 0.0% | 1.4% | +35.5% |
| 13 | REGENTS OF THE UNIVERSITY OF CALIFORNIANEW | 635,131 | $5.1M | 0.1% | 1.2% | new |
| 14 | STATE STREET CORP | 608,838 | $4.9M | 0.0% | 1.1% | +71.9% |
| 15 | BAKER BROS. ADVISORS LP | 555,555 | $4.5M | 0.0% | 1% | 0.0% |
| 16 | StepStone Group LP | 523,467 | $4.2M | 0.3% | 1% | +32.4% |
| 17 | SOROS CAPITAL MANAGEMENT LLC | 484,672 | $3.9M | 2.1% | 0.9% | 0.0% |
| 18 | MILLENNIUM MANAGEMENT LLC | 419,095 | $3.4M | 0.0% | 0.8% | +215.1% |
| 19 | Walleye Capital LLCNEW | 391,273 | $3.1M | 0.0% | 0.7% | new |
| 20 | CANADA PENSION PLAN INVESTMENT BOARD | 379,024 | $3.0M | 0.0% | 0.7% | 0.0% |
| 21 | CITADEL ADVISORS LLC | 354,016 | $2.8M | 0.0% | 0.7% | +2618.4% |
| 22 | FRANKLIN TEMPLETON INC | 350,000 | $2.2M | 0.0% | 0.6% | 0.0% |
| 23 | Affinity Asset Advisors, LLC | 298,001 | $2.4M | 0.1% | 0.6% | +204.1% |
| 24 | UBS Group AG | 278,904 | $2.2M | 0.0% | 0.5% | +5.7% |
| 25 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 259,531 | $2.1M | 0.0% | 0.5% | +42.5% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.